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Abstract
Outbreaks of Dengue impose a heavy economic burden on developing countries in terms of vector
control and human morbidity. Effective vaccines against all four serotypes of Dengue are in
development, but population replacement with transgenic vectors unable to transmit the virus
might ultimately prove to be an effective approach to disease suppression, or even eradication. A
key element of the refractory transgenic vector approach is the development of transgenes that
effectively prohibit viral transmission. In this report we test the effectiveness of several
hammerhead ribozymes for suppressing DENV in lentivirus-transduced mosquito cells in an
attempt to mimic the transgenic use of these effector molecules in mosquitoes. A lentivirus vector
that expresses these ribozymes as a fusion RNA molecule using an Ae. aegypti tRNAval promoter
and terminating with a 60A tail insures optimal expression, localization, and activity of the
hammerhead ribozyme against the DENV genome. Among the 14 hammerhead ribozymes we
designed to attack the DENV-2 NGC genome, several appear to be relatively effective in reducing
virus production from transduced cells by as much as 2 logs. Among the sequences targeted are 10
that are conserved among all DENV serotype 2 strains. Our results confirm that hammerhead
ribozymes can be effective in suppressing DENV in a transgenic approach, and provide an
alternative or supplementary approach to proposed siRNA strategies for DENV suppression in
transgenic mosquitoes.
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Background
Dengue viruses (DENV); (Flaviviridae), etiologic agents of
dengue fever (DF) and dengue hemorrhagic fever/dengue
shock syndrome (DHF/DSS), are transmitted to human
populations by the mosquitoes Aedes aegypti and  Ae.
albopictus. An estimated 50–100 million cases of DF are
reported each year, with 500,000 cases of DHF/DSS and
more than 20,000 deaths [1]. Several factors that contrib-
ute to the emergence of this disease complex include the
collapse of mosquito vector control, the demise of public
health programs, mosquito drug resistance, climatic
changes, expanding urbanization and increased global
travel and commerce [2,3]. While promising vaccine can-
didates are undergoing clinical trials [4], these vaccines
will not be available for general use for quite some time.
Alternative strategies targeting DENV in mosquito cells
and tissues have demonstrated some promise for suppres-
sion of the virus in mosquito vector populations. Modi-
fied antisense oligonucleotides [5], induction of RNA
interference (RNAi) using both preM-derived sense and
antisense encoding sequences expressed from dsSIN virus
vectors [6,7] and hairpin dsRNA to mediate RNAi in both
mosquito cells [8,9] and transgenic mosquitoes [10,11]
have each provided significant levels of DENV suppres-
sion.
While RNAi may be an effective mechanism to interrupt
viral infection, it also has several potential limitations.
Targeted sequences must be at least 21 nt in length limit-
ing the number of target sequences that are conserved
among all DENV strains, and escape mutants can result
from a single point mutation among the 21 nt of target
sequence [12]. RNAi requires a relatively large amount of
dsRNA to be effective against viral replication [13], and
some viruses may replicate faster than the ability of the
RNAi response to suppress the virus [3]. A number of
plant and animal RNA viruses effectively escape the RNAi
response by encoding proteins that suppresses RNA
silencing [10,14,15]. Flaviviruses, in particular, seem to
evade the RNAi response by sequestering their replication
complex inside a double-layered membrane complex
[11].
In an attempt to overcome some of these limitations of
RNA-based effector strategies, our lab has focused efforts
on RNA-enzyme (ribozyme) mediated viral suppression.
In this report we explore the utility of a genetic approach
utilizing hammerhead ribozymes (hRz) for suppression
of DENV in mosquito cells. hRz can inhibit the replication
of a number of RNA viruses including human immunode-
ficiency virus (HIV; [16,17], hepatitis B virus (HBV;
[18,19] and hepatitis C virus (HCV; [20]. These molecules
are capable of identifying targets as small as 15 nt in
length, potentially allowing highly conserved sequences
to be the focus of attack.
In this report we transduced Ae. albopictus (C6/36) cells
with pantropic retroviral vectors, each expressing one of
14 anti-DENV hRz driven from the Ae. aegypti tRNAval pro-
moter. These ribozyme-transduced cells were challenged
with virus and assayed for productivity. Northern analy-
ses, immunofluorescence assays, and quantitative real-
time PCR demonstrate that C6/36 cells expressing several
hRzs were able to suppress DENV replication by at least
75%, with four of these hRzs providing 90 to 99% sup-
pression. Several of these targeted sequences are highly
conserved among DENV serotypes, and may facilitate the
application of this approach to transgenic mosquitoes.
Results
Construction of retroviral transducing vectors expressing 
anti-DENV hRzs and establishment of transduced C6/36 
cells
hRz are small ribonucleic-based enzymes that are capable
of catalyzing target RNA cleavage in a sequence-specific
manner. Their mechanism of action involves the pairing
of the 5' helix I and 3' helix III arms of the hRz to comple-
mentary 3' and 5' base pairs, respectively, on the target
RNA (Fig. 1A). The catalytic core of the hRz, or helix II, is
responsible for cleavage at a 5'-NUH-3' triplet site on the
target RNA, where N can be any of the four nucleotides
and H can be A, C or U [21]. Factors that contribute to the
success of hRzs as effector genes include (i) high concen-
tration and stability of the hRz within the cellular environ-
ment, (ii) colocalization of the hRzs to the target RNA
[22,23] and (iii) accessibility of the hRzs to the cleavage
site within the context of RNA secondary structure [24].
The addition of a tRNAval pol III promoter upstream of the
hRz-coding sequence ensures high production of hRz
transcripts and facilitates their transport to the cell cyto-
plasm [25], overcoming the rate-limiting step of the hRz
cleavage mechanism.
We identified the Ae. aegypti tRNAval sequence from the
GenBank database based upon homology to the Dro-
sophila melanogaster tRNAval sequence. The presumptive
Ae. aegypti tRNAval  (GenBank accession: CC142986),
shared a 95% similarity (e = 5 × 10-27) to the D. mela-
nogaster tRNAval, including both internal promoter sites
(Fig. 1B). This sequence was PCR amplified from Ae.
aegypti  genomic DNA and placed into a pLXRN vector
upstream of inserted hRz sequences as detailed in Materi-
als and Methods. A stretch of 60 adenylic acids (A) was
linked downstream from the hRz sequences to enhance
their catalytic activity by interacting with intracellular
RNA helicases [26,27] and improving access to target sites
on the viral genome (Fig. 1C).Virology Journal 2009, 6:73 http://www.virologyj.com/content/6/1/73
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A: Representative hRz structure and its DENV target sequence Figure 1
A: Representative hRz structure and its DENV target sequence. hRz # 1 nucleotide sequence and structure is 
depicted. Nucleotides flanking the cleavage site (yellow box) in the envelope protein region of the DENV-2 target RNA are 
enlarged. The ribozyme cleaves the target RNA at the GUC triplet site following antisense recognition and base pairing of the 
two ribozyme arms. B: Nucleotide alignments of the Human (Hs), D. melanogaster (Dm), and Ae. aegypti (Aa) tRNAval. The posi-
tion of the concensus internal A and B blocks of the RNA pol III promoter are indicated. C: Plasmid pLAeRzARH was derived 
from pLXRN as described in Materials and Methods. The RSV promoter was added to drive independent expression of the 
hygromycin resistance gene. Expression of each hRz is driven by the tRNAval internal RNA pol III promoter to optimize expres-
sion and translocation of the hRzs to the cytoplasm, and a stretch of 60As is attached to the 3' end of the hRz sequence for 
recruitment of RNA helicase.Virology Journal 2009, 6:73 http://www.virologyj.com/content/6/1/73
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Fourteen ribozyme-encoding retroviruses and one control
lacking a ribozyme sequence were used to transduce wild-
type C6/36 cells by infecting at an MOI of 30 as described
in Materials and Methods. Retrovirus-infected C6/36 cells
were placed under hygromycin selection for 4–8 weeks
and then analyzed for hRz expression by RT-PCR of total
cellular RNA (Fig. 2). Only cells that are transduced will
have integrated provirus cDNA transcribing the hRz RNA.
Therefore, we can be certain that the detected RNA is not
residual lentivirus genomic RNA.
CPE of DENV infection in the hRz-transduced C6/36 cells
The CPE of DENV-2 NGC infection in C6/36 cells, charac-
terized by syncytium formation and decreased cell prolif-
eration, was clearly visible 5 days post infection (dpi).
Those cells expressing certain hRz exhibited a clear reduc-
tion in CPE at 5 dpi, allowing them to grow to confluency,
while cells that lack hRz, (i.e. No-hRz and wild-type),
exhibited the expected CPE (Fig. 3). The most effective
hRz constructs were those that appeared to completely
suppress CPE. These were hRz-C6/36 cell lines # 2, 5, 7
and 11.
Northern analyses for DENV genome
Those transduced cultures that gave at least moderate CPE
suppression were analyzed by Northern blot with DENV-
specific probes to determine the impact of hRz expression
on DENV RNA replication. Infected and uninfected wild-
type C6/36 cells were included as positive and negative
controls, respectively, with β-actin serving as an internal
hybridization and loading control. Autoradiographs (Fig.
4A and 4B) were scanned and analyzed by densitometry
to estimate the relative amounts of DENV RNA in each
sample.
The rapid degradation of ribozyme cleavage products cou-
pled with the very effective suppression of DENV replica-
tion in the transduced cells, made detection of hRz
RT-PCR of total RNA extracted from hRz-C6/36 cells Figure 2
RT-PCR of total RNA extracted from hRz-C6/36 cells. (A) hRz expression in the cells was detected by the presence of 
an hRz-specific band at about 100 bp. Primers for each hRz-C6/36 cells were specific to the hRz insert except for the control 
lacking a hRz sequence (-Rz) for which the primers were specific to tRNAval and poly(A) tail. (B) Wild-type C6/36 cells failed to 
give a PCR product when tested with 15 sets of primers (each primer was specific to each hRz). 1–14: 14 different hRz-C6/36 
cells; -Rz: C6/36 cells without the hRz insert; wt: wild-type C6/36 cells; CtrlP: plasmid DNA control for PCR amplification; M: 1 
Kb Plus DNA ladder; +RT: reactions with reverse transcriptase; -RT: reactions without reverse transcriptase.
A.
B.Virology Journal 2009, 6:73 http://www.virologyj.com/content/6/1/73
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cleavage product RNAs difficult by Northern blots. The
efficacy of the hRzs was estimated by comparing the rela-
tive amount of the target DENV RNA to the infected and
uninfected C6/36 control cultures (Fig. 4C). These analy-
ses confirm that hRz-C6/36 cell lines # 2, 5, 7 and 11 sup-
pressed the replication of DENV by at least 25% relative to
the infected wild-type cells.
In vitro analyses of hRz cleavage activity
Because the Northern analyses did not allow detection of
ribozyme cleavage products, we tested the four most effec-
tive ribozymes for their cleavage activity in vitro. DNA
molecules encoding each hRz construct, including the
tRNAval and polyA tail, were synthesized downstream of a
T7 promoter sequence, cloned, and expressed in vitro as
described in Materials and Methods. These in vitro tran-
scribed ribozymes were combined with in vitro transcribed
target RNA molecules containing extensive regions of the
DENV-2 NGC genome that encompass hRz # 2 and 5, or
hRz # 7 and 11 cleavage sites. The results for two of these
ribozymes, hRz # 2 and # 7, are presented in Fig. 5. The
cleavage products and hRzs are apparent as distinct bands
in the lanes corresponding to each reaction. A third band
of unknown identity was detected in each experimental
lane as well. We believe this extra fragment is the result of
alternative cleavage of the target RNA since the size of the
hRz transcripts (50 nt) are too small to appear on these
gels, and because these fragment do not appear in the con-
trol lanes lacking hRz.
TCID50 immunofluorescence assays
We determined the effectiveness of each ribozyme in sup-
pressing overall infectious virus production using an
immunoflourescence-based TCID50assay. Cell culture
CPE due to DENV infection of C6/36 cells at 5 dpi Figure 3
CPE due to DENV infection of C6/36 cells at 5 dpi. 
Images were taken at the 40× magnification. Cells were 
those transduced with hRz-encoding retroviruses and 
selected in hygromycin for stable integration of the trans-
gene. Representative infected cell cultures are shown. These 
are cells transduced with (A) hRz # 2, (B) hRz # 5, (C) hRz # 
7, (D) hRz # 11, (E) No Rz (transduced with lentivirus vector 
lacking a hRz) or (F) non-transduced C6/36 cells.
Northern hybridization analysis of DENV-2 replication in  cells expressing hRz constructs Figure 4
Northern hybridization analysis of DENV-2 replica-
tion in cells expressing hRz constructs. (A) Total RNA 
samples hybridized with DENV-specific probes. (B) Actin 
RNA from the same samples hybridized with a β-actin-spe-
cific probe. Each construct is indicated by numbers; i: wild-
type C6/36 infected with DENV; u: uninfected wild-type C6/
36. The autoradiograph was exposed for 6 hr prior to devel-
oping. (C) Quantification of relative DENV-2 RNA levels 
from the Northern blot analysis. The scanned autoradio-
graph was processed in ImageJ software and the relative 
amount of DENV-2-specific RNA in each sample was com-
pared against that of infected wild-type cells using an 
ANOVA test (GraphPad Prism 3.0). Statistically significant 
differences relative to the Infection control (Dunnett's post-
test, p < 0.01) are indicated with asterisks. Infected: infected, 
non-transduced C6/36 cells; Uninfected: uninfected, non-
transduced C6/36 cells; Rz #: Different infected hRz cells.
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Confirmation of cleavage activities for representative hRzs Figure 5
Confirmation of cleavage activities for representative hRzs. (A and B) Maps showing the in vitro transcripts generated 
from the linearized pET11a vectors for the hRz # 2 (A) and hRz # 7 (B) target substrates. Positions of the T7 promoter (T7-
Pro), hRz-T7 cleavage site (hRz7), T7 terminator (T7 Term), and Cla I site used for linearization (Cla I) are indicated. T1 and T2 
show the extent of two transcripts that are generated in the in vitro transcription reaction for each substrate. C1 shows the 
extent of the single 5' cleavage product from both transcripts from each substrate, while C2 and C3 show the extent of the 
two 3' cleavage products generated from the two different transcripts produced from each substrate. (C) Agarose gel of in vitro 
cleavage reaction products. In vitro transcribed targets and their respective hRz # 2 and hRz # 7 were incubated for 30 min at 
37°C. Cleavage products were separated in 2% agarose gels stained with ethidium bromide. Lane M: Millenium™ RNA Marker. 
Lanes 1–3: In vitro transcribed DENV-ENV region target without MgCl2 (lane 1), hRz # 2 and without MgCl2 (lane 2), and hRz # 
2 with MgCl2 (lane 3). Lanes 4–6: In vitro transcribed 3'NCR region target without MgCl2 (lane 4), hRz # 7 without MgCl2 (lane 
5), and hRz # 7 with MgCl2 (lane 6). Arrows in lanes 3 and 6 show the expected hRz # 2 and hRz#7 cleavage products, respec-
tively.Virology Journal 2009, 6:73 http://www.virologyj.com/content/6/1/73
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medium collected at 4 dpi from infected cells was assayed
as described in Materials and Methods using a DENV
envelope protein-specific monoclonal antibody. While all
ribozyme transformed, and even the No-hRz transformed
control cells, exhibited statistically significant reductions
in overall infectious virus production, hRz-C6/36 cell
lines # 2, 5, 7 and 11 had remarkably reduced DENV-2 tit-
ers, as much as 2 orders of magnitude, compared to
infected wild-type cells (Table 1 and Fig. 6). The fact that
the No-hRz control did have reduced yields of virus can be
attributed to the hygromycin selection protocol, which
did impact the virus infectivity in transformed cells to
some extent.
Real-time PCR quantitation of DENV titer in whole cell 
RNA
The ability of each hRz to suppress DENV genome replica-
tion was quantitatively evaluated for the hRz expressing
C6/36 cells using qRT-PCR to detect virus genomes in cell
lysates. Total cellular RNA was extracted 7 dpi from
infected hRz-transduced cells following the protocol
described in Materials and Methods. First-strand cDNA
was prepared using the Capsid2 primer (Table 2), fol-
lowed by 40 rounds of PCR amplification using primers
Capsid2 F and R. The absolute quantity of viral RNA was
determined based upon comparison of infected cell Ct
values against those of viral RNA standards.
Table 1: Tabulation of data for TCID50 and qRT-PCR analyses of hRz effectiveness
TCID50 qRT-PCR Cells qRT-PCR Supernatant
Avg SE Avg SE Avg SE Avg % Red
Infected 4.39 × 106 7.12 × 105 1.77 × 106 4.17 × 105 2.92 × 106 1.38 × 106 0
Uninfected 2 1 3 2 3 1 N/A
No-hRz 1.88 × 106 5.94 × 105 1.37 × 106 2.53 × 105 1.60 × 106 6.46 × 105 41.71
Rz # 1 8.77 × 105 3.42106 1.62 × 106 3.13 × 105 9.46 × 105 2.70 × 105 52.03
Rz # 2 2.78 × 104 1.09 × 104 5.88 × 104 3.95 × 104 5.37 × 104 1.65 × 104 98.07
Rz # 3 1.16 × 106 6.89105 1.68 × 106 3.38, × 105 1.39 × 106 7.62 × 105 43.62
Rz # 4 2.37 × 106 1.14 × 106 1.99 × 106 2.61 × 105 1.51 × 106 7.58 × 105 27.39
Rz # 5 3.08 × 104 9.1 × 103 9.65 × 104 4.90 × 104 9.44 × 104 2.18 × 104 96.87
Rz # 6 2.33 × 105 1.16 × 105 1.65 × 106 1.97 × 105 6.45 × 105 1.76 × 105 59.74
Rz # 7 2.72 × 104 1.13 × 104 9.56 × 104 2.04 × 104 4.98 × 104 2.49 × 104 97.42
Rz # 8 1.87 × 105 1.26 × 105 6.46 × 105 2.51 × 105 4.95 × 105 2.43 × 105 80.76
Rz # 9 8.50 × 104 3.46 × 104 2.51 × 105 1.24 × 105 3.24 × 105 1.45 × 105 90.92
Rz # 10 4.07 × 105 2.34 × 105 5.11 × 105 1.39 × 105 1.36 × 105 4.71 × 104 85.74
Rz # 11 2.47 × 104 4.01 × 103 3.55 × 104 1.59 × 104 2.11 × 104 7.41 × 103 98.90
Rz # 12 5.49 × 105 1.61 × 105 5.51 × 105 3.17 × 105 3.43 × 105 2.06 × 105 81.54
Rz # 13 3.06 × 105 1.08 × 105 3.60 × 105 2.11 × 105 1.90 × 105 1.65 × 105 88.73
Rz # 14 1.98 × 105 1.22 × 105 2.63 × 105 1.07 × 105 2.63 × 105 2.20 × 105 90.53
Averages of results from four separate infections (Avg) are presented for each type of analysis along with Standard Error of the Mean (SE). The 
average percent reduction for all tests (Avg % Red) relative to the Infected cell control is calculated in the final column.Virology Journal 2009, 6:73 http://www.virologyj.com/content/6/1/73
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Four independent experiments were compared for each
hRz-C6/36 transduced cell line to insure consistency and
reproducibility. The results (Table 1 and Fig. 7A) for most
of the hRz were consistent with the IFA determination of
virus titer, with hRz-C6/36 cell lines # 2, 5, 7 and 11
exhibiting suppression of DENV replication by up to
nearly 100 fold compared to the infected wild-type sam-
ples. However, the results for hRz # 6 were remarkably dif-
ferent from those obtained with the IFA analysis,
suggesting this ribozyme may be interfering with viral
genome packaging or assembly rather than replication.
Real-time PCR quantitation of DENV titer in cellular 
medium
To evaluate the impact of hRzs on assembly and release of
DENV, we performed qRT-PCR on the viral RNA extracted
from cell supernatant of the infected hRz-C6/36 cells. Cell
supernatants collected at one hour prior to whole cell
RNA extraction were immediately processed for RNA
extraction, cDNA synthesis and RT-PCR procedures (see
Materials and Methods). The results (Table 1 and Fig. 7B)
demonstrated that the titers of extracellular virus genomic
RNA obtained for hRz-C6/36 cell lines # 2, 5, 7 and 11
were consistent with genome copies detected in whole cell
extracts. Similar levels of reduction were seen for most of
the other hRz as well. Together, these qRT-PCR findings
confirmed that most of the highly effective hRzs affected
viral RNA replication and not DENV assembly and release
from the cells.
The levels of extracellular virion RNA for hRz # 6 were
more closely related to the TCID50 results than to the qRT-
PCR results of total cellular RNA, reinforcing the possibil-
ity that this ribozyme's effect was related to interference
with virion production rather than direct suppression of
viral genomes.
Discussion
We have confirmed the effectiveness of expressed hRzs as
suppressive agents of DENV in transduced mosquito cells.
These ribozymes have the ability to cleave their target RNA
at an NUH triplet site, and may recycle themselves pro-
vided there are short sequence homologies between the
ribozyme arms and the corresponding target sequence.
This could provide an advantage over standard antisense
RNAs that act stoichiometrically and do not destroy the
function of the targeted RNAs [28].
In this study, the ribozymes were expressed under the con-
trol of the Ae. aegypti tRNAval promoter. Human tRNAval
TCID50 immunofluorescence assay Figure 6
TCID50 immunofluorescence assay. At 4 day dpi, cells 
were fixed and stained. Primary antibody against ENV pro-
tein and biotinylated-secondary antibody and streptavidin 
were employed as a fluorescence detection system. A one-
way ANOVA test was performed using GraphPad Prism 3.0 
software. Asterisk indicate no significant differences relative 
to the Infected control (Dunnett's, p < 0.01). Rz # 1–14: 14 
different infected hRz cells; No Rz: infected C6/36 cells trans-
duced with the lentivirus vector lacking a hRz insert.
Infected
Uninfected
No-hRz
Rz# 1
Rz# 2
Rz# 3
Rz# 4
Rz# 5
Rz# 6
Rz#7
Rz#8
Rz#9
Rz# 10
Rz# 11
Rz# 12
Rz#1 3
Rz#1 4
1.0 100
1.0 101
1.0 102
1.0 103
1.0 104
1.0 105
1.0 106
1.0 107
*
D
E
N
V
 
T
i
t
e
r
Table 2: Designations and base sequences of twelve primer sets evaluated to select optimal primer pairs for detection of the DENV-2 
NGC RNA genome
Designation Primer sequences (5'→3')
Capsid1 2F: caatatgctgaaacgcgaga 2R: ccatcactgttggaatcagc
Capsid2 3F: caatatgctgaaacgcgaga 3R: cgccatcactgttggaatc
Capsid3 4F: gcgagaaatacgcctttcaa 4R: ccatcactgttggaatcagc
Capsid4 5F: tatgctgaaacgcgagagaa 5R: cgccatcactgttggaatc
Capsid5 6F: gcgagaaatacgcctttcaa 6R: cgccatcactgttggaatc
Capsid6 7F: atgctgaaacgcgagagaaac 7R: ccctgctgttggtgggatt
NS51 2F: tcaaaagcattcagcacctg 2R: cacatttgggcgtaggactt
NS52 3F: gcaatgtatgccgatgacac 3R: caggtgctgaatgcttttga
NS53 4F: gcaatgtatgccgatgacac 4R: tcaggtgctgaatgcttttg
NS54 5F: tggaggagccttagtgagga 5R: acgtcccaaggttttgtcag
NS55 6F: tgagcaagaaagagggagga 6R: caggtgctgaatgcttttga
NS56 7F: caaaagcattcagcacctgaca 7R: gttaaagcgcttgcgaacct
F and R: forward and reverse primer, respectively.Virology Journal 2009, 6:73 http://www.virologyj.com/content/6/1/73
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A: Absolute quantitation of genome equivalents in cells infected with DENV and expressing hRzs Figure 7
A: Absolute quantitation of genome equivalents in cells infected with DENV and expressing hRzs. Viral RNA 
samples were obtained from total cell RNA extraction at 7 dpi. ANOVA test was performed using GraphPad Prism 3.0 soft-
ware. Asterisk indicate no significant differences relative to the Infected control (Dunnett's, p < 0.01). Plot is based on the 
average titer from 4 independent experiments. Rz # 1–14: 14 different infected hRz cells; No Rz: infected C6/36 cells trans-
duced with the lentivirus vector lacking a hRz insert. B: Absolute quantitation of viral titers from different hRz cells. Viral RNA 
samples were obtained from collected cell supernatant at 7 dpi. ANOVA test was performed using GraphPad Prism 3.0 soft-
ware. Asterisk indicate no significant differences relative to the Infected control (Dunnett's, p < 0.01). Rz # 1–14: 14 different 
infected hRz cells; No Rz: infected C6/36 cells trasnduced with the lentivurs vector lacking a hRz insert. Plots are based on the 
average titer from 4 independent experiments.
Real-Time  PCR: Infected cells
Infected
Uninfected
No-hRz
Rz# 1
Rz# 2
Rz# 3
Rz# 4
Rz# 5
Rz# 6
Rz# 7
Rz# 8
Rz# 9
Rz# 10
Rz# 11
Rz# 12
Rz# 13
Rz# 14
1.0 100
1.0 101
1.0 102
1.0 103
1.0 104
1.0 105
1.0 106
1.0 107
** ** * *
D
E
N
V
 
G
e
n
o
m
e
 
 
E
q
u
i
v
a
l
e
n
t
s
A.
Real-Time  PCR: Cell supernate
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has been used successfully to enable suppression of target
genes by driving the expression of hRzs [29,30]. The tRNA-
val utilizes RNA pol III which is involved in the transcrip-
tion of short RNAs [31] and yields transcription levels 2–
3 orders of magnitude greater than that of pol II systems
[32]. Linking hRzs to a tRNAval also enhances their activity
by increasing resistance to RNases, since intracellular sta-
bility is one of the most important determinants of
ribozyme efficacy [33], and facilitates the cytoplasmic
transport of the attached ribozyme [25] where it can be
co-localized with replicating DENV RNA.
Since intramolecular base pairing within the complex
structure of the long DENV genomic RNA could preclude
the association of ribozymes with their target sequences,
we designed our hRz to include a 3' terminal 60 adenylic
acids. This poly(A) sequence acts to recruit the unwinding
activity of endogenous RNA helicase [34]. Hybrid
ribozymes with this poly(A) tail are able to cleave target
RNAs possessing complex secondary structure that hRz
without accessory helicases cannot act upon [26,35]. In
addition, the effect of helicase-attached hRzs is signifi-
cantly greater than those of the conventional parental
ribozymes [27].
Retroviral vectors offer a number of advantages over other
gene transfer methods for the transduction of somatic
cells, and have been widely used as gene delivery systems.
They have the ability to stably integrate the genes they vec-
tor into host cell chromosomes with high transduction
efficiencies [36-38]. Pseudotyped retroviruses displaying
the vesicular stomatitis virus G glycoprotein (VSV-G) are
able to transduce any dividing cells without the require-
ment for cell receptors [39]. This pantropic retroviral sys-
tem has been successfully employed for transduction of
mosquito cells [40]. In our experiments, we used self-inac-
tivating retrovirus vectors having a defective 3' U3 that is
duplicated as part of the 5' LTR during reverse transcrip-
tion, allowing the hRz transgene to be expressed by the
internal tRNAval promoter and decreasing the possibility
of promoter interference [36,41]. Transduced hRz cells
were selected for hygromycin resistance for longer than 2
months. Though it is likely that less than 100% of these
resistant cells were transformed, the majority of them
appear to bear functional hRz vectors within the genome
as indicated by the RT-PCR results of expressed hRz RNA.
In addition, because these cells were transduced using len-
tivitus vectors, there is no real possibility that expression
of the hRz came from the non-integrated vector.
Transduction of C6/36 cells by means of pantropic retro-
virus vectors resulted in stable genomic integration and
expression of the hRzs, rendering them persistently resist-
ant to DENV. Since pools of transduced cells were used for
the DENV challenge assays, the observed inhibition
effects are not likely due to clonal variation or differing
copy number of the constructs within the transduced cell
population. However, this approach does allow the possi-
bility that individual cells in the pools may be more sus-
ceptible to DENV and thus contribute to the majority of
virus detected. In addition, the lower antiviral activity
seen for some hRzs might also reflect a distribution effect
leading to a wide range of hRz expression levels in the
transduced cell cultures [17,42].
We designed 14 hRzs that target different regions along
the DENV-2 genome. Quantitative real-time PCR and
immunofluorescence assays demonstrate that C6/36 cells
expressing certain hRzs were able to suppress DENV-2
NGC viral replication by at least 25%, with hRz-C6/36 cell
lines # 2, 5, 7 and 11 having a more pronounced effect, of
nearly 2 logs (100 fold) reduction in viral titer compared
to the untransduced C6/36 cells. These IFA results corre-
spond well with data obtained from the Northern hybrid-
ization analyses for those hRzs examined.
We were unable to detect the cleaved RNA products by
Northern analyses due to two factors. First, there is likely
rapid degradation of the DENV RNA within the cells after
they are cleaved. Second, the hRz expressing cells are
"armed" with many hRz molecules, and upon infection
by the virus there is little chance for initiation of a produc-
tive infection during which DENV target RNA might build
up to levels that cleavage products might become appar-
ent. We interpret these results to demonstrate that sup-
pression of virus, when it occurs, is so effective that little
new viral RNA target is actually produced, and few cleav-
age products would be expected to be evident.
With the exception of hRz # 11, the three most active hRzs
target the GUC triplet site which is cleaved most efficiently
compared to other triplets [43]. GUC is frequently chosen
as the target in many hRz studies because of its wide
occurrence in natural hRz motifs [28]. The No-hRz trans-
duced cells, which lack the hRz insert, exhibited no signif-
icant suppression of DENV replication, verifying that
decreased levels of viral titers requires the presence of the
hRz [44] and is not simply due to the presence of the
transducing retrovirus or hygromycin selection.
Ng et al. reported 12% reduction of the krr1 gene expres-
sion in Giardia canis in cells without a hRz motif and
attribute the observation to an antisense effect of the hRz
forming a complex with the mRNA, inhibiting its transla-
tion and promoting its degradation [45]. While we cannot
rule out an antisense effect for our hRzs, the in vitro anal-
yses of ribozyme cleavage activity demonstrated that they
were catalytically active. Hence, the cleavage activity ofVirology Journal 2009, 6:73 http://www.virologyj.com/content/6/1/73
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ribozymes within cellular environments would be
expected to occur. The reduction in functional full-length
DENV RNA was consistent with the cleavage effects of the
ribozymes since the effectiveness of the hRzs we examined
correlates very well with the realative effectiveness of the
core cleavage site in that three of the four most effective
hRzs target a GUC triplet, supporting the catalytic nature
of the hRzs effectiveness and arguing against a simple
antisense effect.
For the most part, the variations in relative effectiveness
that we observed among the 14 hRz we analyzed can be
explained by less efficient cleavage activity resulting in
incomplete inhibition of DENV replication. However,
there are several alternative possibilities unrelated to hRz
catalysis that could influence their effectiveness. These
include (i) the presence of mismatched bases in the hRz
arm, especially with shorter effectors [46], due to viral
escape mutants, (ii) integration of the hRz construct into
an inactive gene expression region of the host cell
genome, and (iii) obscuring of the target triplet site by
RNA-binding proteins [28,47]. Since our experiments
were done over a short time frame and with multiple rep-
licates we can rule out the selection of escape mutations as
the cause of weak suppression. Our RT-PCR analyses of
the expressed hRz RNA in transformed cells did not show
an appreciable difference in levels of expression, allowing
us to rule out position effects on expression levels as a fac-
tor. The only possibility we cannot rule out in our experi-
ments is the interference by RNA binding proteins at the
target site.
hRz # 6 exhibited a somewhat different result from all
other hRzs when comparing the relative levels of DENV-
specific RNA between cellular and extracellular RNAs by
qRT-PCR. The results for hRz # 6 suggest cellular DENV-
specific RNA levels were not reduced to comparable levels
as extracellular DENV-specific RNA levels. This implies
that the reductions in virus titer observed with hRz # 6 are
not related to reductions in viral RNA synthesis in infected
cells, but may result from affects on packaging of the viral
genomes and/or assembly and release of virions. Because
hRz # 6 was not among the most effective hRzs tested, we
did not pursue examination of this phenomenon.
While we were able to target several sequences that are
common to all DENV serotype 2 strains, we were unable
to identify suitable cleavage sites that were conserved
among all DENV serotypes. Several highly conserved
sequences are present among all DENV serotypes, but the
requirement for an NUH triplet cleavage site makes these
conserved sequences useless as targets for the hRz strategy.
Other ribozymes having less stringent cleavage site
requirements may be more appropriate for these con-
served sequences.
Our results are comparable with results obtained from
sense/antisense and siRNA strategies for suppression of
DENV. dsSIN may be used in transient expression systems
to validate these strategies in either cell cultures or mos-
quitoes [6,7] but retroviral vectors and transduced mos-
quito cells are more appropriate for examining the
effectiveness of transgene suppression strategies in
somatic cells because they allow a closer approximation of
the actual endpoint of these strategies, transgenic mos-
quito tissues. Our results suggest the best application of
this effector molecule is to constitutively express the hRz
in target cells since DENV undergoes rapid RNA synthesis
at 3–6 hours post infection and release of infectious viri-
ons after 12 hours. Transgenic cells pre-primed with
expressed hRzs are able to act instantly in inhibiting viral
replication upon entry.
Neither our hRz approach nor the siRNA strategy is
wholey effective against viral escape mutants. However,
one potential obstacle in using RNAi is the evidence for
viral RNAi suppressors which have been reported in
plants, poliovirus, and HIV-1 variants [48-50]. In the case
of DENV, the presence of viral RNAi suppressors may con-
tribute to persistent infections in which DENV is able to
replicate in cells without causing cytopathic effect. hRzs
are not subject to suppression by viral gene products,
which could be an advantage when applied as an anti-
DENV effector gene.
A number of RNA viruses exhibit significant genetic varia-
tion due to error-prone replication machinery. The simul-
taneous use of multiple ribozymes attacking two or more
sites on the same target RNAs may be advantageous since
it helps minimize loss of ribozyme activity due to base-
pairing mismatches from mutation of one or the other tar-
geted sites. However, simultaneous expression of two dif-
ferent ribozymes within the same transduced cell pool did
not enhance the reduction of DENV titers (data not
shown). Our results indicate the same levels of inhibition
as obtained with the single hRz approach. This lack of syn-
ergy when two independent hRzs area employed might be
caused by structural changes within the target RNA fol-
lowing the cleavage by one hRz that alter the cleavage
domain for the second hRz, interfering with its ability to
anneal with the substrate. Similar results have been
reported by Xu et al., 1999, in which the expression of
human insulin-like growth factor II is not completely
inhibited by double hRzs but yields the same efficacy as
single hRzs. As an alternative approach, we are currently
exploring combining two hRzs as a so-called MaxizymeVirology Journal 2009, 6:73 http://www.virologyj.com/content/6/1/73
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[25,29,30,51,52] that targets two regions with low toler-
ance for sequence variation, and may ultimately provide
even better suppression of DENV replication in trans-
duced mosquito cells and tissues.
Our results demonstrate that the hRz approach has signif-
icant potential as a strategy for suppressing DENV in
transgenic mosquitoes, either alone or in combination
with alternative genetic suppression strategies. While
complete suppression of virus infectivity in infected mos-
quito tissues may not be possible, significant reduction of
virus titers within mosquito tissues could result in a
decreased efficiency of transmission for the virus, thereby
reducing the prevalence of the disease among associated
human populations.
Materials and methods
Ae. aegypti tRNAval identification
We used the tRNAval sequence identified by the fruit fly
genome survey (NT_037436 REGION: complement
(1342674613426818)) as a query for a BLASTN search.
We limited our search to Ae. aegypti instances in the
Genome Survey Sequence database. The search returned
one hit bearing a 95% similarity (e = 5 × 10-27) to the D.
melanogaster  tRNAval, including both internal promoter
sites. We then used the mFold [53] software and found the
typical cloverleaf structure indicative of tRNA folding. We
then added the extended stem region used by Kuwabara et
al. [30] and analyzed the predicted folding pattern with
mFold again.
Selection of hRz target sites on DENV-2 genome
Genomic sequences of 29 strains of DENV-2 were
retrieved from GenBank, aligned in ClustalX [54,55], and
hRz target sites were selected by scanning for conserved
sequences that contain one of the following triplets; GTC,
GTA, ATC or CTC. These triplets are believed to be the
most effective target sites for hRz cleavage activity [28].
The primary criterion for selection was that the target site
must be present in all 29 strains of DENV-2 (DENV-2-
hRz), or present only in DENV-2 NGC (DENV-2 NGC-
hRz). Another important criterion for selecting suitable
sites for hRz cleavage was the length of conserved flanking
arms which determine the level of specificity of the
ribozyme. In this study, the length of each arm ranges
from 5–10 bp. The sequences of hRz templates, positions
of the triplets on DENV genome, and the specific strains
of DENV-2 NGC they match are listed in Table 3.
Table 3: Sequence, positions, and tropism of each of the 14 ribozymes used in this study
hRz # Sequence of target RNA (5'→3') Target triplet and position in genome DENV-2 strains targeted
1 AGGAAAAGUCGUGCAAC GUC 1325 (ENV) NGC
2 GUUUUAGGUCGCCUGAU GUC 1988 (ENV) NGC
3 UAGCCCAGUCAACAUAG GUC 2035 (ENV) NGC
4 CAUAGGAGUCAUUAUCA GUC 2323 (ENV) NGC
5 UCACUGUCUGUGUC GUC 2367 (ENV) All strains
6 AUAGUGUCAUCAGUGAA GUC 8272 (NS5) All strains
7 AAAGAAGUCAGGCCA GUC 10420 (3'NCR) All strains
8G C A U G GUACCUGUGG GUA 4503 (NS2B) All strains
9 GACUCAAAACUCAUGUCAGC CUC 2974 (NS1) All strains
10 AUGGAAAUCAGACCATT AUC 3430 (NS1) All strains
11 GGAAGCUGUACGCAUGG GUA 10528 (3'NCR) All strains
12 UGAAGCUGUAGUCUC GUA 10624 (3'NCR) All strains
13 AUGCCAUCCAUGAA AUC 10244 (NS5) All strains
14 CUGUUGAAUCAACAGGU AUC 10768 (3'NCR) All strains
Underlined: core NUH tripletVirology Journal 2009, 6:73 http://www.virologyj.com/content/6/1/73
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Plasmid construction
The hRz expression plasmid, pLAeRzARH (Figure 1), con-
tains a given hRz-encoding gene under the control of the
Ae. aegypti tRNAval promoter. This is followed by a 60As
tail that promotes hRz accessibility. A hygromycin resist-
ance gene under control of a Rous Sarcoma Virus (RSV)
promoter permits selection of transfected cells. The back-
bone was derived from pQCXIH retroviral vector (Clon-
tech, Mountain View, CA). To assemble this construct,
pQCXIH was digested with Xba I and EcoR V to eliminate
the original IRES-hygromycin fragment from the plasmid.
The RSV promoter was amplified from pLXRN (Clontech)
using the following primer set; forward 5' TAAT
TCTAGACCGTGCGGCCGCAGATCCCCTCAGGATATAG-
TAGT TTC 3' and reverse 5' ACCAGATATCACGCGT-
GCGAAACGATCCTCATCCTGTCTCTT 3'. The PCR
product was isolated from a 0.9% agarose gel using the
QIAquick Gel Extraction Kit (Qiagen, Valencia, CA). The
amplified RSV promoter was inserted into the digested
vector at the Xba I and EcoR V sites to create pQCXR. The
hygromycin resistance gene was amplified by PCR from
pQCXIH using the following primers; forward 5' ATC-
GACGCGTATGGATAGATCCGGAAAGCCTGAA CTCA C
CGCGACG 3' and reverse 5' ATCGACGCGTCCCC CCT
TTTTCTGGAGACTAAATAAAATCTT 3'. The amplified
product was purified as above and inserted into pQCXR
between the Mlu I and EcoR V sites to obtain pQCXRH.
pQCXRH was then cut with Xba I and treated with antarc-
tic phosphatase (AP) (New England Biolabs (NEB),
Ipswitch, MA) to reduce self-ligation. The 60As tail was
constructed by performing a one-cycle PCR amplification
using a forward primer: 5' ATCGTCTAGAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAATTTTTTACTAGTCGTA 3', which also acted
as a PCR template, and a reverse primer: 5' TACGACTAG-
TAAAAAATTTTTTTTTTTTT 3'. The PCR product was
directly purified by phenol-chloroform extraction and
ethanol precipitation and double digested with Xba I and
Spe I before ligating with pQCXRH linearized with Xba I
to create pQCARH. Our novel Ae. aegypti tRNAval pro-
moter gene was synthesized from two oligonucleotides
using Klenow large fragment DNA polymerase (NEB) and
a pair of primers; forward – 5' ATCGTCTAGACCGT TGG
TTTCCGTAGTGTAGTGGTTATCACGTCTGCTTCACACG-
CAGAAGGTCCCCGGTTCGAACCC 3' and reverse – 5'
ATCGTCTAGACGATCAATTGCAGTCTCGAGAAAGTTTG
GTTTTTGTAGTGCCCGGGTTCGAACCGGGGACCTTCT-
GCG 3'. The amplified product was purified as above,
digested and ligated into pQCARH at the unique Xba I
site. To achieve higher packaging efficiency, the entire
insert spanning the Ae. aegypti tRNAval promoter to the
hygromycin resistance gene was inserted into pLXRN
(Clontech). The RSV-neomycin resistance gene originally
present in pLXRN was eliminated by digestion with Sph I
and Csp45 I, followed by end-filling with Klenow frag-
ment and ligation. To obtain pLAeARH, the region from
Ae. aegypti tRNAval promoter to the hygromycin resistance
gene from pQAeARH was amplified by PCR using the fol-
lowing primer set; forward 5' ATTAGGATCCTCTAGAC-
CGTTGGTTTCCGTAGTG 3' and reverse 5' ATTACCTA GG
GATATCCTGTCTTTAACAAATTGGACTAATC 3' and
inserted into the modified pLXRN plasmid using Avr II
and BamH I sites. hRz genes were then inserted between
Csp45 I and Mfe  I sites. hRz templates (Table 4) were
amplified using the following set of primers; forward 5'
ATCGACGCGTATGGATAGATCCGGAAAGCCTGAACTC
ACCGCGACG 3' and reverse 5' GATGAATTCAAAAAA
ACAA TTGT 3'. The PCR product was purified as above
and cut with Csp45 I and Mfe I before insertion into pLAe-
ARH, generating pLAeRzARH. Restriction analysis and
DNA sequencing were performed after each cloning step
to confirm correct base sequences. All plasmids were puri-
fied by CsCl2 gradient centrifugation.
Retroviruses
Retroviruses encoding the 14 hRzs and No-hRz control
were produced following established methods [56].
Briefly, the retroviruses were assembled by simultaneous
transfection of 293FT cells (Invitrogen, Carlsbad, CA)
with the pLAeRzARH (5 μg) and plasmids encoding
murine leukemia virus gag-pol (5 μg) and the vesicular
stomatitis virus (VSV) envelope protein (2 μg). The VSV
envelope protein confers broad host range and allows
high efficiency transduction of the transgene into Aedes
cells [39]. After 48 hr, culture supernatants containing the
retroviruses were collected and filtered through a 0.45 um
filter to remove cell debris. Virus was then applied to tar-
get cells or stored frozen at -80°C until required.
Cell Culture
Maintenance
Ae. albopictus (C6/36) mosquito cells used in this study
were maintained in complete L-15 (Atlanta Biologicals)
with 10% FBS (Atlanta Biologicals), 10% tryptose phos-
phate broth (Sigma), and 1% antibiotic/antimycotic solu-
tion (Sigma). hRz transduced cells were maintained in
complete L-15 with 35 μg/mL hygromycin (Invitrogen).
For infection of cells, complete L-15 without any antibiot-
ics was used. Cells were incubated at 28°C without CO2.
Infection with retroviruses and selection of transduced cells
Wild-type C6/36 cells in 6-well plates were infected with
retroviruses at an MOI of 30. After 24 hr, the medium was
replaced and the cells were allowed to grow for one week
before being transferred to T25 flasks. Complete L-15
medium with hygromycin B was added to the T25 flasks
after 72 hr to select stably transduced cells.
Infection with DENV-2 NGC
Wild-type C6/36 cells were seeded at a density of 0.5 × 106
cells/mL in 6-well plates and incubated for 2 hr at 28°C to
allow attachment. Once attached, cells were washed twiceVirology Journal 2009, 6:73 http://www.virologyj.com/content/6/1/73
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with medium and challenged with DENV-2 NGC stock at
an MOI of 0.01. Infection was allowed to continue for 7
days at 28°C before viral RNA was extracted both from
cells and cultured supernatants using TRI reagent (Invitro-
gen), and purified QIAamp Viral RNA Mini Kit (Qiagen),
respectively.
Northern analysis
Total RNA was extracted using TRI reagent (Invitrogen),
and 10 μg was loaded on 1% denaturing agarose gels.
RNA was transferred overnight onto nylon membranes,
and the membranes were fixed by UV cross linking, prehy-
bridized in Church Buffer (67 g Na2HPO4, 2 ml H3PO4,
70 g SDS in 1 L distilled water; filter sterilized before use)
for an hour, and then hybridized with specific 32P-labeled
probe overnight in a 65°C oven. The membranes were
washed 2× with washing solution 1 (2× SSC, 0.1% SDS),
and another 2× with washing solution 2 (0.2× SSC, 0.1%
SDS), each wash at 65°C for 25–30 minutes. The DNA
probes were designed to detect different regions along the
virus genome and were synthesized using Prime-A-Gene
Kit (Promega, Madison, WI). Unincorporated unlabelled
nucleotides were removed by QIAquick Gel Extraction Kit
(Qiagen) before use. The β-actin gene was used as an
internal control for RNA extraction and hybridization.
After washing, the autoradiograph was exposed for 6–16
hours before developing. The autoradiograph was
scanned and the relative amount of viral RNA in each
sample was determined by densitometry using ImageJ
Java image processing software http://rsb.info.nih.gov/ij/
index.html. Measurements for each sample were normal-
ized to that of infected wild-type cells to determine the rel-
ative virus replication efficiency.
In vitro analysis of hRz cleavage activity
The procedure for in vitro hammerhed ribozyme cleavage
reactions was adapted from Shao Y. et al [57]. Two com-
plementary oligonucleotides containing the hRz catalytic
core sequence flanked by the sequences of the two bind-
ing arms and a T7 promoter sequence were synthesized
(Invitrogen) and annealed together in equimolar concen-
trations using the following conditions: 10 mM Tris-HCl
pH 8.0, 50 mM NaCl. The reaction was heat denatured at
95°C for 5 min followed by slow cooling to room temper-
ature. The annealed templates were cloned into the
pET11a plasmid (Novagen) and linearized with Cla I for
in vitro run-off transcription.
Primer sets were used to PCR amplify a 1370 bp target
spanning the 1497–2866 bp envelope region (ENV for-
ward – 5' TTTTAAAATTCTAGAGAGAACGGGCCTC-
GACTT 3', and reverse – 5' TTTAAATTTAGAT CTCTC TGT
TTGTGTTGGGGCATT 3') and a 940 bp target spanning
the 9774–10713 bp 3'NCR (NCR forward – 5' AAAT-
TAAAATCTAGAAGTTCCATGCAGAAACCAAG 3', and
Table 4: Sequences of the fourteen ribozyme templates used for 
PCR amplification
hRz # Template sequence for amplification (5' to 3')
1 CCGGTTCGAACCCGGGCACTACAAAAACCAACAAgt
tgcacCTGATGAGGCCGAAAGGCCGAAActtttcctA
CAATTGTTTTTTTGAATTCATC
2 CCGGTTCGAACCCGGGCACTACAAAAACCAACAAat
caggcCTGATGAGGCCGAAAGGCCGAAAcctaaaac
ACAATTGTTTTTTTGAATTCATC
3 CCGGTTCGAACCCGGGCACTACAAAAACCAACAAct
atgttCTGATGAGGCCGAAAGGCCGAAActgggctaA
CAATTGTTTTTTTGAATTCATC
4 CCGGTTCGAACCCGGGCACTACAAAAACCAACAAtg
ataatCTGATGAGGCCGAAAGGCCGAAActcctatgA
CAATTGTTTTTTTGAATTCATC
5 CCGGTTCGAACCCGGGCACTACAAAAACCAACAAg
acacaCTGATGAGGCCGAAAGGCCGAAAcagtgaAC
AATTGTTTTTTTGAATTCATC
6 CCGGTTCGAACCCGGGCACTACAAAAACCAACAAtt
cactgatCTGATGAGGCCGAAAGGCCGAAAcactatA
CAATTGTTTTTTTGAATTCATC
7 CCGGTTCGAACCCGGGCACTACAAAAACCAACAAtg
gcctCTGATGAGGCCGAAAGGCCGAAActtctttAC
AATTGTTTTTTTGAATTCATC
8 CCGGTTCGAACCCGGGCACTACAAAAACCAACAAc
cacaggCTGATGAGGCCGAAAGGCCGAAAccatgcA
CAATTGTTTTTTTGAATTCATC
9 CCGGTTCGAACCCGGGCACTACAAAAACCAACAAg
ctgacatCTGATGAGGCCGAAAGGCCGAAAgttttgag
tcACAATTGTTTTTTTGAATTCATC
10 CCGGTTCGAACCCGGGCACTACAAAAACCAACAAa
atggtctCTGATGAGGCCGAAAGGCCGAAAtttccatA
CAATTGTTTTTTTGAATTCATC
11 CCGGTTCGAACCCGGGCACTACAAAAACCAACAAc
catgcgCTGATGAGGCCGAAAGGCCGAAAcagcttcc
ACAATTGTTTTTTTGAATTCATC
12 CCGGTTCGAACCCGGGCACTACAAAAACCAACAAg
agacCTGATGAGGCCGAAAGGCCGAAAcagcttcaA
CAATTGTTTTTTTGAATTCATC
13 CCGGTTCGAACCCGGGCACTACAAAAACCAACAAtt
catgCTGATGAGGCCGAAAGGCCGAAAtggcatACA
ATTGTTTTTTTGAATTCATC
14 CCGGTTCGAACCCGGGCACTACAAAAACCAACAAa
cctgttCTGATGAGGCCGAAAGGCCGAAAttcaacag
ACAATTGTTTTTTTGAATTCATC
Bold uppercase: conserved catalytic core. Lowercase: 5' and 3' arms 
of the hRz, respectively.Virology Journal 2009, 6:73 http://www.virologyj.com/content/6/1/73
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reverse – 5' ATTTTATTTAGATCTGATTCAACAGCACCAT-
TCCA 3') from the DENV-2 NGC Infectious Clone vector.
The envelope region contains hRzs # 2 and 5 sites while
the 3'NCR region contains hRzs # 7 and 11 sites. The
amplified fragments were digested with Xba I and Bgl II
and cloned into the Xba I and BamH I-digested pET11a
vector.
2.5 ug of linearized ribozyme plasmid and 1.5 ug of
ribozyme template were in vitro transcribed using the
Megashortscript and Megascript (Ambion, USA), respec-
tively. In vitro transcription reactions were performed fol-
lowing the manufacturer's protocol with incubation for 4
hr at 37°C. The transcripts were phenol: choloroform: iso-
amylalcohol (24:25:1) extracted, choloroform: isoamyal-
cohol (24:1) extracted and ethanol precipitated with 0.2
ug of glycogen. The RNA concentration was measured
spectrophotometrically.
In vitro transcribed targets (10 pM) were mixed with 50
pM of ribozymes in 50 mM Tris-HCl, pH-8.0, heat dena-
tured at 85°C for 3 min, and snap cooled in ice. The cleav-
age reaction was initiated by addition of 20 mM MgCl2,
and 40 U of RNase inhibitor and incubated at 37°C for 30
min. Loading buffer II (Ambion) was added and the reac-
tion mixture was incubated at 65°C for an additional 5
min followed by electrophoresis in a 2% agarose/formal-
dehyde/MOPS gel [57] for 1 hr at 105 V. After electro-
phoresis the gel was stained with ethidium bromide and
photographed with UV illumination.
TCID50 immunofluorescence assay
Supernatants containing virus from infected cells were
collected 4 dpi and were 10-fold serially diluted in a 96-
well plate. C6/36 cells from a confluent flask were then
added to the mix and the cultures were incubated for 4
days at 28°C without CO2. After incubation, cells were
fixed with acetone:DPBS (3:1) and stained with primary
antibody (1:200) specific to the envelope (ENV) protein
of DENV [58]. Detection of positive DENV-infected cells
was accomplished by utilizing a biotinylated-secondary
antibody and streptavidin detection system (Amersham
Biosciences, Piscataway, NJ). Cells that showed fluores-
cence within the cytoplasm were scored as positive for
DENV infection. The TCID50 was calculated based on Kar-
ber's method [59]. The titer was expressed as
log10TCID50/0.1 ml.
Real-Time PCR
Run mode and machine
All absolute quantitation experiments in this study were
performed under the 9600 Emulation run mode of
AB7500 Fast machine from Applied Biosystems (Foster
City, CA). The PCR profile was 1 cycle of 50°C for 2 min,
1 cycle of 95°C for 10 min and 40 cycles of 95°C for 15
sec and 60°C for 1 min. Dissociation curve analysis was
added to the end of each run. This was initiated by heating
the PCR product to 95°C and holding it for 15 sec. Then
the denatured DNA was allowed to anneal by ramping
down to 60°C for 1 min. The temperature was then slowly
ramped up again to 95°C for 15 sec and fluorescence sig-
nal was collected during this time. Once the temperature
reached 95°C, the PCR run was terminated. Results were
analyzed using the company's Sequence Detection Soft-
ware Version 1.3.
Determination of hRz retroviral titers
Retroviral RNA was extracted using the QIAamp Viral RNA
Mini Kit (Qiagen) following the manufacturer's protocol
without any modification. The primers used to detect ret-
roviral transcripts were specific to a region corresponding
to the packaging signal of the retrovirus. Standard curves
were generated based upon known titers of a control virus,
pLeGFP, for which the titer was determined by counting
GFP expressing cells in a limiting dilution assay (3 × 106
colony forming units per ml).
Evaluation and selection of the primer set used for detection of 
DENV-2 NGC RNA
Viral RNA was extracted from infected C6/36 cells 7 dpi
using QIAamp Viral RNA Mini Kit (Qiagen). Twelve sets
of primers were evaluated for detection of the capsid and
NS5 regions of the DENV-2 NGC RNA viral genome
(Table 2). All primers were designed using the Primer3
freeware website http://frodo.wi.mit.edu/cgi-bin/
primer3/primer3_www.cgi. An optimal primer pair was
chosen based on a standard curve (slope value ranges
within -2.8 to -3.2 and R2 value ranges within 0.970 to
0.999) and a single specific peak on a dissociation curve
generated after the PCR run. Slope values of -3.2 indicated
100% amplification efficiency and R2 values of 1.000 sug-
gested the perfect fit of standard curve data to a straight
line. Dissociation curves were plotted after the run to
assure the specificity of the PCR product. Higher peaks
displayed at Tm of 80°C indicated a specific PCR product
while sub peaks at a lower Tm represented primer-dimers
and non-specific PCR products. The primer pair, forward
5' CAATATGCTGAAACGCGAGA 3' and reverse 5'
CGCCATCACTGTTGGAATC 3', was chosen for further
experiments as it offered the highest amplification effi-
ciency and gave a single specific PCR product.
Preparation of DENV-2 standard curve
Wild-type C6/36 cells were infected with the DENV-2
NGC strain and viral supernatants were collected 7 dpi.
Virus titers were determined by tissue culture infectious
dose 50% (TCID50) immunofluorescence assays using a
primary antibody against the virus envelope. Viral RNA
was extracted as described above and cDNA was synthe-
sized through reverse transcription with MuLV reverseVirology Journal 2009, 6:73 http://www.virologyj.com/content/6/1/73
Page 16 of 17
(page number not for citation purposes)
transcriptase (Applied Biosystems) and 5-fold serially
diluted for generation of the standard curve.
Preparation of viral RNA samples
Viral RNA from infected cells was extracted using the TRI
reagent (Invitrogen). RNA concentrations were deter-
mined spectrophotometrically. Viral RNAs were extracted
from collected supernatants as mentioned above. cDNAs
of each sample were synthesized as described above, and
the titers of DENV from each sample were determined
based on a standard curve. The presence of a single spe-
cific PCR product was also confirmed via a dissociation
curve.
Statistics
ANOVA test was performed using GraphPad Prism 3.0
software. Means were considered statistically significant
when p-values less than 0.01 were obtained with the Dun-
nett's post-test. Lack of statistical significance with regards
to Infection control is indicated on all figures as asterisks
above bars.
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